Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis.

Sigurgeirsson B, Ghannoum M.

Expert Opin Investig Drugs. 2012 Oct;21(10):1549-62. Epub 2012 Aug 9. Review.

PMID:
22876754
2.

Evaluation of the morphological effects of TDT 067 (terbinafine in Transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo.

Ghannoum M, Isham N, Henry W, Kroon HA, Yurdakul S.

Antimicrob Agents Chemother. 2012 May;56(5):2530-4. doi: 10.1128/AAC.05998-11. Epub 2012 Feb 21.

3.
4.

Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations.

Ghannoum M, Isham N, Herbert J, Henry W, Yurdakul S.

J Clin Microbiol. 2011 May;49(5):1716-20. doi: 10.1128/JCM.00083-11. Epub 2011 Mar 16.

5.
6.

Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome®) in patients with onychomycosis.

Dominicus R, Weidner C, Tate H, Kroon HA.

Br J Dermatol. 2012 Jun;166(6):1360-2. doi: 10.1111/j.1365-2133.2011.10766.x. No abstract available.

PMID:
22136723
7.
9.

Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature.

Gupta AK, Gregurek-Novak T, Konnikov N, Lynde CW, Hofstader S, Summerbell RC.

J Cutan Med Surg. 2001 May-Jun;5(3):206-10. Epub 2001 May 2. Review.

PMID:
11685666
10.
11.

Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison.

Sigurgeirsson B, Elewski BE, Rich PA, Opper C, Cai B, Nyirady J, Bakshi R.

J Dermatolog Treat. 2006;17(1):38-44.

PMID:
16467022
12.

Permeation studies of novel terbinafine formulations containing hydrophobins through human nails in vitro.

Vejnovic I, Huonder C, Betz G.

Int J Pharm. 2010 Sep 15;397(1-2):67-76. doi: 10.1016/j.ijpharm.2010.06.051. Epub 2010 Jul 8.

PMID:
20620203
13.

Iontophoretic terbinafine HCL 1.0% delivery across porcine and human nails.

Amichai B, Mosckovitz R, Trau H, Sholto O, Ben-Yaakov S, Royz M, Barak D, Nitzan B, Shemer A.

Mycopathologia. 2010 May;169(5):343-9. doi: 10.1007/s11046-009-9265-x. Epub 2009 Dec 13.

PMID:
20012894
14.

Cytoplasmic fungal lipases release fungicides from ultra-deformable vesicular drug carriers.

Steinberg G.

PLoS One. 2012;7(5):e38181. doi: 10.1371/journal.pone.0038181. Epub 2012 May 29.

16.

Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week).

Takahata Y, Hiruma M, Shiraki Y, Tokuhisa Y, Sugita T, Muto M.

Mycoses. 2009 Jan;52(1):72-6. doi: 10.1111/j.1439-0507.2008.01531.x. Epub 2008 Apr 26.

PMID:
18444971
17.

Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study.

Amichai B, Nitzan B, Mosckovitz R, Shemer A.

Br J Dermatol. 2010 Jan;162(1):46-50. doi: 10.1111/j.1365-2133.2009.09414.x. Epub 2009 Jul 20.

PMID:
19785609
19.

Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US.

Van Duyn Graham L, Elewski BE.

Mycoses. 2011 Nov;54(6):e679-85. doi: 10.1111/j.1439-0507.2011.02038.x. Epub 2011 Jun 12. Review.

PMID:
21668517
20.

Terbinafine. An update of its use in superficial mycoses.

McClellan KJ, Wiseman LR, Markham A.

Drugs. 1999 Jul;58(1):179-202. Review.

PMID:
10439936
Items per page

Supplemental Content

Write to the Help Desk